Amgen Foundation deepens commitment to aspiring scientists worldwide by expanding Amgen Scholars Program
- Details
- Category: Amgen
The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-year, $21 million commitment brings the program to a total of 24 elite institutions across the U.S., Europe, Asia and, for the first time, Australia and Canada.
Boehringer Ingelheim inaugurates new centre for agile working methods
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site. The sustainably built and innovative building was handed over to its future users at an internal ceremony.
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
- Details
- Category: AstraZeneca
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
- Details
- Category: Novartis
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. Xofluza is a first-in-class, single-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease, an enzyme essential for viral replication.
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
- Details
- Category: AstraZeneca
AstraZeneca, and its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company's oncology portfolio and bringing new medicines to patients more quickly.
Alcon to develop SMART Suite digital health platform for cataract surgery
- Details
- Category: Novartis
Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve cataract surgery for surgeons and patients.
More Pharma News ...
- FDA approves asthma indication for Dupixent® (dupilumab)
- Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies
- US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
- Amgen launches AMGEVITATM (biosimilar adalimumab) in markets across Europe
- Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
- Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India
- Abbott names Robert B. Ford president, chief operating officer